Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

Apichat Jariyavilas,1 Nuntika Thavichachart,2 Ronnachai Kongsakon,3 Sunanta Chantakarn,4 Suwanna Arunpongpaisal,5 Vasu Chantarasak,6 Piyadit Jaroensook,7 Khanogwan Kittiwattanagul,8 Osot Nerapusee9 1Srithanya Hospital, Department of Mental Health, Ministry of Public Health, Bangkok, 2Department of...

Full description

Bibliographic Details
Main Authors:	Jariyavilas A, Thavichachart N, Kongsakon R, Chantakarn S, Arunpongpaisal S, Chantarasak V, Jaroensook P, Kittiwattanagul K, Nerapusee O
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-01-01
Series:	Neuropsychiatric Disease and Treatment
Subjects:	Schizophrenia hostility aggression disturbing behavior paliperidone ER
Online Access:	https://www.dovepress.com/effects-of-paliperidone--extended-release-on-hostility-among-thai-pati-peer-reviewed-article-NDT

Similar Items

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
by: Kongsakon R, et al.
Published: (2017-10-01)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
by: Yang FD, et al.
Published: (2017-04-01)

Mania associated with paliperidone treatment in schizophrenia: A case report
by: Süleyman Demir, et al.
Published: (2015-09-01)

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?
by: Suttajit S, et al.
Published: (2015-09-01)

Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double-blind, multicentric trial
by: Sandip Shah, et al.
Published: (2011-01-01)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
by: Zhang LL, et al.
Published: (2016-01-01)

Paliperidone palmitate-induced sialorrhoea
by: Cengiz Cengisiz, et al.
Published: (2016-03-01)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
by: Shi C, et al.
Published: (2016-08-01)

Decision analytic economic paliperidone ER in relapsing schizophrenic patients in Italy
by: Patrizia Berto, et al.
Published: (2008-06-01)

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
by: Ali Abdall-Razak, et al.
Published: (2019-09-01)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
by: Emsley R, et al.
Published: (2018-01-01)

Quality of life of patients suffering from schizophrenia and treated with long-acting risperidone and paliperidone-palmitate
by: Mihajlović Filip, et al.
Published: (2018-01-01)

Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
by: Amber N. Edinoff, et al.
Published: (2021-09-01)

Different effects of paliperidone and risperidone therapy on blood lipid and Hcy metabolism as well as endocrine hormones in patients with schizophrenia
by: Bei-Fang Fan, et al.
Published: (2017-11-01)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
by: Gattaz WF, et al.
Published: (2020-09-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li HF, et al.
Published: (2015-12-01)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
by: Rita deAzevedo Avelar, et al.
Published: (2020-12-01)

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
by: Adam J. Savitz, et al.
Published: (2019-04-01)

Dose Adjustment Model of Paliperidone in Patients With Acute Schizophrenia: A post hoc Analysis of an Open-Label, Single-Arm Multicenter Study
by: Tianmei Si, et al.
Published: (2021-08-01)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
by: Emsley R, et al.
Published: (2017-08-01)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
by: Carpiniello B, et al.
Published: (2016-05-01)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
by: Brasso C, et al.
Published: (2017-11-01)

The hostility toward women scale
by: Check, James Victor Patrick
Published: (2014)

Psychotic experiences and aggression inoutpatients with schizophrenia
by: Konstantinos Tsirigotis, et al.
Published: (2013-12-01)

Paliperidone induced neutropenia in first episode psychosis: a case report
by: Natalie Martos, et al.
Published: (2021-02-01)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
by: Mathews M, et al.
Published: (2020-06-01)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
by: Lambert M, et al.
Published: (2020-12-01)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
by: Chen CY, et al.
Published: (2018-03-01)

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola Danielle, et al.
Published: (2012-03-01)

Comparative study on clinically latent aggressiveness inoutpatients with schizophrenia treated with classical antipsychotics and with risperidone
by: Konstantinos Tsirigotis, et al.
Published: (2014-03-01)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
by: Hodgson RE
Published: (2019-08-01)

Şizofreni tanısı olan iki kadında gebelik ve lohusalık dönemi boyunca paliperidon palmitat kullanımının anne ve yeni doğan üzerine etkileri
by: Esin ERDOĞAN, et al.
Published: (2017-12-01)

Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
by: Alexander Hodkinson, et al.
Published: (2021-08-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
by: Zhao JP, et al.
Published: (2017-08-01)

Catatonia Associated with Initiating Paliperidone Treatment
by: Nathanael J. McKeown, et al.
Published: (2010-05-01)

Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
by: Jeffrey P. Anderson, et al.
Published: (2017-10-01)

First-Degree Atrioventricular Block with Tachycardia from Paliperidone and Mirtazapine Overdose
by: Brian Cheung, et al.
Published: (2020-09-01)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
by: Li G, et al.
Published: (2021-10-01)